Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals") and Formation Bio today announced Formation Bio's acquisition of worldwide rights, excluding Greater China, to ...
Formation Bio and Lynk Pharmaceuticals today announced Formation Bio's acquisition of worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant ...
Formation Bio is inking a deal worth more than $600 million in biobucks for ex-China rights to a next-gen immunology asset ...
Pilates is known as a relatively low-risk exercise modality—it's low-impact, done with lightweights, and is easily adaptable ...
NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI), a clinical-stage biopharmaceutical company developing brain-penetrant therapeutics for central nervous system (CNS) cancers, today announced newly ...
Singing and chanting can have profound benefits to physical, mental and social health, with both immediate and long-term effects ...
9d
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor
BGE-102 was well-tolerated in SAD and initial MAD cohorts, with a pharmacokinetic profile supporting once-daily oral dosingStrong target ...
After a yearslong series of setbacks, NASA's Escape and Plasma Acceleration and Dynamics Explorers, or ESCAPADE, mission has ...
New ideas can shift everything you thought you understood, and these science books offer that rare spark that leaves your ...
ZURZUVAE ™ is a neuroactive steroid (NAS) that acts as a positive allosteric modulator of GABA-A receptors, enhancing inhibitory signalling in the brain. The GABA system is the major inhibitory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback